Investors in Altimmune, Inc. Invited to Join Securities Fraud Class Action with Schall Law Firm

Altimmune, Inc. Securities Fraud Lawsuit

In a significant development for investors, the Schall Law Firm has opened the doors for stakeholders of Altimmune, Inc. to lead a class action lawsuit following alleged securities fraud. This litigation targets violations of the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a), as well as Rule 10b-5, which has drawn attention from both current and former investors.

Case Overview

The lawsuit pertains to claims that Altimmune made misleading statements regarding the performance of its drug candidate, Pemvidutide. Initially, the company had presented Pemvidutide as a key asset, especially ahead of results from the critical IMPACT Phase 2B MASH trial. Unfortunately, when the trial results were made public, they revealed a failure to achieve statistically significant outcomes in its primary endpoints.

Despite these disappointing results, Altimmune suggested a positive outlook for its Phase 3 trial, which further led investors to place their trust in the company's purported capabilities. These misleading assertions have raised questions about the integrity of the information provided by Altimmune throughout the class period from August 10, 2023, to June 25, 2025.

Call to Action for Investors

Investors who acquired Altimmune securities during this period and experienced financial loss are strongly encouraged to reach out to Schall Law Firm. The firm is not only familiar with shareholder rights but also specializes in securities litigation and can provide insights into the legal avenues available for claim recovery. Interested parties must act before the deadline of October 6, 2025, to ensure participation in the class action.

To connect, investors can reach Brian Schall through the Schall Law Firm's office at 310-301-3335, or via the firm's website at www.schallfirm.com.

The Importance of Class Certification

It is important to note that the class in this case has yet to receive certification. Without certification, prospective plaintiffs will find themselves unrepresented. Therefore, potential class members should consider their next steps soon, as remaining aloof could mean acceptance of their status as absent class members.

As more details unfold regarding the company’s missteps, monitoring the lawsuit’s progress will be crucial. Investors need to be aware of potential shifts in the market that may impact not only Altimmune's trajectory but also access to legal relief for financial damages suffered during this turbulent period.

Conclusion

This class action lawsuit presents a pivotal opportunity for Altimmune investors looking to reclaim their losses due to alleged securities fraud. With the representation by Schall Law Firm, investors can secure legal guidance during these complex proceedings. If you believe you have a basis for participation in this class, take action and reach out to understand your rights fully. Stay informed and proactive as developments arise, as this litigation could serve as a significant legal battleground for shareholder rights.